Revue Médicale Suisse
September 16, 2026
Rayan Nasserdine, Laura Xhymshiti, Anne-Charlotte Paporé et al.
Intravenous (IV) ketamine is a rapidly acting therapeutic option for the management of treatment-resistant depression and acute suicidal crisis. Unlike conventional antidepressants, its effects may occur within hours, allowing a rapid reduction in suicidal ideation and psychological distress. Its use remains specialized and requires hospital-based care with medical monitoring and a...
Molecular Psychiatry
May 29, 2026
Mickael Eskinazi, Rayan Nasserdine, Romane M Cusin et al.
Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transition remains unclear. We conducted a...
Molecular Psychiatry
March 1, 2025
Michel Sabé, Adi Sulstarova, Alban Glangetas et al.
39 citations
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of...
Frontiers in Psychiatry
2025
Alexandre Fraichot, Sophie Favre, Hélène Richard-Lepouriel
1 citation
Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...
Annales Médico-psychologiques revue psychiatrique
July 10, 2024
Federico Seragnoli, Gabriel Thorens, Louise Penzenstadler et al.
8 citations
Dans cet article, nous avons pour objectif de décrire un modèle interdisciplinaire de psychothérapie assistée par psychédéliques (PAP) que nous avons développé dans un cadre institutionnel aux hôpitaux universitaires de Genève. La psychothérapie assistée par psychédéliques (PAP) est une approche psychothérapeutique exploitant l’altération de l’état de conscience induite par une substance...